Nuveen LLC Makes New Investment in Ironwood Pharmaceuticals, Inc. $IRWD

Key Points

• Nuveen LLC invested approximately $693,000 in Ironwood Pharmaceuticals, purchasing 471,361 shares during the first quarter, increasing its ownership to 0.29%.
• Other institutional investors significantly increased their stakes, with Connor Clark & Lunn Investment Management increasing its holdings by 335.8% and GSA Capital Partners boosting by 3,683.6%.
• Ironwood Pharmaceuticals' stock was upgraded to a "strong-buy" rating by Wall Street Zen, with the company reporting earnings of $0.14 per share against a consensus estimate of ($0.02).

Nuveen LLC acquired a new stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 471,361 shares of the biotechnology company's stock, valued at approximately $693,000. Nuveen LLC owned about 0.29% of Ironwood Pharmaceuticals at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in IRWD. Point72 Asia Singapore Pte. Ltd. acquired a new position in Ironwood Pharmaceuticals during the 4th quarter worth approximately $36,000. MetLife Investment Management LLC grew its position in Ironwood Pharmaceuticals by 10.6% during the 4th quarter. MetLife Investment Management LLC now owns 89,255 shares of the biotechnology company's stock valued at $395,000 after purchasing an additional 8,559 shares during the last quarter. Hsbc Holdings PLC lifted its stake in shares of Ironwood Pharmaceuticals by 88.9% in the 4th quarter. Hsbc Holdings PLC now owns 20,886 shares of the biotechnology company's stock worth $91,000 after purchasing an additional 9,828 shares during the period. Dimensional Fund Advisors LP increased its position in Ironwood Pharmaceuticals by 4.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 218,422 shares of the biotechnology company's stock worth $968,000 after purchasing an additional 10,149 shares during the last quarter. Finally, ProShare Advisors LLC lifted its stake in Ironwood Pharmaceuticals by 28.9% in the fourth quarter. ProShare Advisors LLC now owns 50,204 shares of the biotechnology company's stock worth $222,000 after acquiring an additional 11,267 shares during the period.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 9th. One research analyst has rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, Ironwood Pharmaceuticals presently has an average rating of "Hold" and a consensus target price of $4.94.

Ironwood Pharmaceuticals Price Performance

NASDAQ IRWD traded down $0.04 during trading on Monday, reaching $1.12. 310,927 shares of the company's stock were exchanged, compared to its average volume of 2,747,856. The business has a 50 day moving average price of $0.93 and a 200-day moving average price of $0.98. Ironwood Pharmaceuticals, Inc. has a fifty-two week low of $0.53 and a fifty-two week high of $5.13. The stock has a market capitalization of $181.11 million, a P/E ratio of -22.30 and a beta of 0.32.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biotechnology company reported $0.14 earnings per share for the quarter, beating analysts' consensus estimates of ($0.02) by $0.16. The business had revenue of $85.24 million during the quarter, compared to analyst estimates of $62.02 million. Ironwood Pharmaceuticals had a negative net margin of 2.25% and a negative return on equity of 2.46%. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.